BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 10, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 12/7 cls
Adolor (ADLR) Pacific Growth Gregory Wade Upgrade Buy (from neutral) 30% $5.07
Wade upgraded the stock after the company partnered with Pfizer (PFE) to develop and commercialize ADLR's ADL5859 and ADL5747 for pain (see B2). He noted that more than half of the $232.5M in milestones can be earned prior to regulatory approval.
Allos (ALTH) Banc of America Securities Katherine Kim New Buy 3% $7.12
Kim set an $11 target. In late 2008, she expects data from the pivotal Phase II PROPEL trial of Pralatrexate (PDX) to treat peripheral T cell lymphoma (PTCL).
ArQule (ARQL) Banc of America Securities Katherine Kim New Buy 0% $6.51
Kim set a $9 target. ARQL recently started two Phase II trials of ARQ 197 to treat microphthalmia transcription factor tumors and pancreatic cancer (see BioCentury, Nov. 5). She believes the stock will be driven by additional Phase II/III trials for the inhibitor of c-Met receptor tyrosine kinase starting in the coming months, potential positive data starting in late 2008, and a possible partnership in 2008-09.
Avigen (AVGN) Punk Juan Sanchez New Buy 0% $4.16
Sanchez set a $7...

Read the full 1198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >